CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Deucrictibant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04618211
NCT04618211Phase 2Completed
CompareCT.gov

A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II

Pharvaris Netherlands B.V.·interventional·Posted Nov 5, 2020·Updated Dec 17, 2025

In Brief

A Phase 2 clinical trial evaluating Deucrictibant and Placebo for Hereditary Angioedema and 9 related conditions. Completed, enrolled 74 participants across 36 sites in 13 countries.

Detailed Summary

This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
CountriesBulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 5, 2020
Enrollment StartFeb 3, 2021
Primary CompletionSep 23, 2022
Study CompletionMar 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.7 years ago

Interventions

Deucrictibantdrug

deucrictibant soft capsules for oral use

Placebodrug

Matching placebo capsules for oral use